Study investigating advanced MRI scans to detect prostate cancer set to begin
the ONA take:
A new technique that employs advanced MRI scans to diagnose prostate cancer is being tested in a nationwide trial. Tim Dudderidge, a consultant urological surgeon based at Southampton General Hospital, one of the ten centers involved in the trial, has cited the shortcomings of the traditional biopsy procedure; men with a raised PSA are typically advised to have a biopsy, but the biopsy may either miss existing cancer or lead to unnecessary surgery in the case of slow-growing cancer.
Traditional technique uses an ultrasound probe to guide a needle through the rectal walls and into the prostate for sample extraction. The procedure is normally performed on a patient under local anesthetic. The new procedure under review uses cutting-edge image technology, multi parametric (MP) MRI, to create very accurate scans to help determine location, size, and aggressiveness of the prostate cancer.
If successful, the advanced MRI technique could eliminate or reduce the need for invasive biopsies in some men, and provide greater detail at an earlier stage for men with conditions that warrant treatment. The trial involves ten centers spread across the country, with the goal to recruit 700 individuals with prostate cancer by October 2015 for participation.
A new technique that employs advanced MRI scans to diagnose prostate cancer is being tested in a nationwide trial.
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|